{
  "id": 19363017,
  "title": "Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition",
  "url": "https://urgent.news/2026/11/10/molidustat-targets-a-synthetic-lethal-vulnerability-in-apc-mutant",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-10T00:00:00.000Z",
  "source": {
    "name": "eLife",
    "slug": "elife",
    "url": "https://elifesciences.org/articles/110991"
  },
  "original_language": "en",
  "account": "Recent research has revealed a potential new approach to treating colorectal cancer (CRC) in patients with APC mutations. Scientists have discovered that Molidustat, a drug that inhibits Prolyl hydroxylase domain (PHD)2, can induce cell death in human APC-mutant colorectal cancer cells. This finding suggests that Molidustat may exploit a metabolic and stress vulnerability present in these cells.\n\nFurther investigation into the mechanisms behind Molidustat's effects led to the identification of glutathione S-transferase P1 (GSTP1) as an off-target of the drug. The researchers demonstrated that Molidustat directly inhibits the enzymatic activity of GSTP1. Importantly, they found that the combined loss of both PHD2 and GSTP1 led to synergistic changes in the cell's proteome, which are associated with suppressed cell cycle progression and apoptotic signaling.\n\nTo confirm their findings, the researchers used mouse organoids, which are miniature versions of human tissue grown in the lab. They observed that APC-mutant mouse organoids were selectively sensitive to Molidustat, and this sensitivity was not seen when the drug was used alone. These results suggest that the anti-tumor activity of Molidustat may be due to a synthetic lethal interaction between GSTP1 and PHD2 in APC-mutant CRCs.\n\nIn summary, this study highlights a novel therapeutic target in colorectal cancer by identifying the functional relationship between GSTP1 and PHD2. The discovery of Molidustat's off-target effect on GSTP1 in APC-mutant cells offers a promising avenue for developing targeted anti-cancer therapies.",
  "summary": "Mutations in the adenomatous polyposis coli (APC) gene are a defining feature of colorectal cancer (CRC) and impose metabolic and stress adaptation requirements that may create exploitable vulnerabilities. Prolyl hydroxylase domain (PHD) inhibitors have been explored as therapeutic agents in CRC; however, their mechanisms of action and off-target effects remain elusive. Serendipitously, we found…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}